A Phase 2 interventional study of Ciliary neurotrophic factor (CNTF) and Surgery in MacTel (Macular Telangiectasia) Type 2, sponsored by Neurotech Pharmaceuticals. Completed at 11 sites in 2 countries. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-09.
Sponsored by Neurotech Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Telangiectasis with a site in United States — 5 open to participants now, 5 under way, 2 of them phase 3. Telangiectasis · United States.
Among the 33 studies in Telangiectasis with a site in United States, this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 2, and was the 21st registered.
69 studies on the registry are indexed under Telangiectasis; 12 are open to participants now.
Browse Telangiectasis studies →5 of the 33 studies in Telangiectasis with a site in United States are open now. Recruiting first, the newest first:
Atavistik Bio, Inc · Sites in United States, Argentina
Ages 18+ · Healthy volunteers
Neurotech Pharmaceuticals · Sites in United States, Australia
Ages 18+
Neurotech Pharmaceuticals · Sites in United States, Australia
Ages 21–80
Cure HHT · Sites in United States
Healthy volunteers
The Lowy Medical Research Institute Limited · Sites in United States, Australia, Germany and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Telangiectasis studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 30 across 59 interventional studies indexed under Telangiectasis.
Median enrollment 20 across the 31 interventional studies, 5,011 across the 2 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
Neurotech Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Neurotech Pharmaceuticals has 7 studies filed under Telangiectasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Telangiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent sham surgery in the respective precursor study (NTMT-01 or NTMT-02).
A substudy was conducted in which subjects enrolled in study (NTMT-02), who had 1 study-eligible eye that underwent sham surgery, were offered the option to have NT-501 implanted in the same study eye. Of the 19 subjects who had 1 study-eligible eye and underwent sham surgery in the Cohort 2 precursor study (NTMT-02), 16 subjects elected to have NT-501 implanted in the same study eye during the substudy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
Biological: Ciliary neurotrophic factor (CNTF) · Procedure: Surgery
Participants completed protocol NTMT-02. Participants for cohort 2 arm were either: * NT-501 group: included subjects who each had 1 study-eligible eye that had NT-501 implanted and a fellow eye that did not undergo any study intervention. * Sham group: included subjects who each had 1 study-eligible eye that underwent sham surgery and a fellow eye that did not undergo any study intervention. * Sham+NT-501 group: included subjects who had both eyes that were study-eligible, and had NT-501 implanted in 1 eye and underwent sham surgery in the contralateral eye.
Biological: Ciliary neurotrophic factor (CNTF) · Procedure: Surgery
The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
Surgery to implant device for NT-501
Sham surgery
Ellipsoid Zone (Area of IS/OS Loss) - Cohort 1
Change from baseline to 72, 84, 96 and 108 months post-surgery (based on participants' original implant date during precursor study) by SD-OCT for Cohort 1
Time frame: 72, 84, 96, and 108 months (based on participants' original implant date during precursor study)
Ellipsoid Zone (Area of IS/OS Loss) - Cohort 2
Change in EZ from baseline to 36, 48, 60 and 72 Months post-surgery (based on participants' original implant date during precursor study). Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up
Time frame: Baseline to 36, 48, 60 and 72 Months post-surgery (based on participants' original implant date during precursor study)
Change in Retinal Sensitivity (dB) From Baseline - Cohort 2 Only
Baseline to 72 Months - analyses also presented for additional times: 36, 48, and 60 Months post-surgery (based on participants' original implant date during precursor study) . Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up in this study.
Time frame: Baseline to 72 Months (based on participants' original implant date)
Change in BCVA From Baseline for Cohort 1
Baseline to 108 Months - analyses also presented for additional times: 84, 96 and 108 Months (based on participants' original implant date)
Time frame: Baseline to 108 Months (based on participants' original implant date)
Change in BCVA From Baseline for Cohort 2
Baseline to 72 Months - analyses also presented for additional times: 36, 48, and 60 Months (based on participants' original implant date during precursor study) . Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up
Time frame: Baseline to 72 Months (based on participants' original implant date)
Change in Reading Speed From Baseline - Cohort 2 Only
Baseline to 72 Months - analyses also presented for additional times: 36, 48, and 60 Months (based on participants' original implant date during precursor study) . Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up. Note: there were
Time frame: Baseline to 72 Months (based on participants' original implant date)
| Milestone | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant |
|---|---|---|---|---|
| Started | 6 | 19 | 15 | 30 |
| Switched to nt-501 | 0 | 16 | 0 | 0 |
| Retained nt-501 throughout the study | 6 | 16 | 14 | 30 |
| Completed | 6 | 18 | 13 | 27 |
| Not completed | 0 | 1 | 2 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Covid-19 | 0 | 1 | 0 | 1 |
| Withdrew: Other health reason | 0 | 0 | 0 | 1 |
Change from baseline to 72, 84, 96 and 108 months post-surgery (based on participants' original implant date during precursor study) by SD-OCT for Cohort 1
| mm2 | Cohort 1 - Fellow Eye | Cohort 1 - NT-501 Implant |
|---|---|---|
| Baseline | 0.697 ± 0.8334 | 0.629 ± 0.08135 |
| 72 Months Post-Surgery Actual | 1.37 ± 1.4648 | 1.137 ± 1.2905 |
| 72 Months Post-Surgery Change from Baseline | 0.620 ± 0.7526 | 0.508 ± 0.6348 |
| 84 Months Post-Surgery Actual | 1.241 ± 1.4691 | 1.132 ± 1.1194 |
| 84 Months Post-Surgery Change from Baseline | 0.705 ± 0.7474 | 0.503 ± 0.5001 |
| 96 Months Post-Surgery Actual | 1.338 ± 1.3264 | 1.169 ± 1.0987 |
| 96 Months Post-Surgery Change from Baseline | 0.642 ± 0.6922 | 0.540 ± 0.5159 |
| 108 Months Post-Surgery Actual | 0.394 ± 0.5156 | 0.301 ± 0.4909 |
| 108 Months Post-Surgery Change from Baseline | 0.165 ± 0.1558 | 0.277 ± 0.4605 |
Change in EZ from baseline to 36, 48, 60 and 72 Months post-surgery (based on participants' original implant date during precursor study). Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up
| mm2 | Cohort 2 - NT-501 Implant | Cohort 2 - Sham |
|---|---|---|
| Baseline | 0.684 ± 0.0707 | 0.766 ± 0.0687 |
| Change at 36 Months Post-Surgery | 0.259 ± 0.0609 | 0.279 ± 0.0585 |
| Change at 48 Months Post-Surgery | 0.360 ± 0.0609 | 0.282 ± 0.0589 |
| Change at 60 Months Post-Surgery | 0.450 ± 0.0644 | 0.105 ± 0.0760 |
| Change at 72 Months Post-Surgery | 0.443 ± 0.0728 | 0.497 ± 0.0680 |
Baseline to 72 Months - analyses also presented for additional times: 36, 48, and 60 Months post-surgery (based on participants' original implant date during precursor study) . Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up in this study.
| dB | Cohort 2 - NT-501 Implant | Cohort 2 - Sham |
|---|---|---|
| Baseline | 25.688 ± 0.3377 | 25.672 ± 0.3317 |
| Retinal Sensitivity Change at 36 Months Post-Surgery | -1.391 ± 0.3377 | -1.054 ± 0.3320 |
| Retinal Sensitivity Change at 48 Months Post-Surgery | -2.312 ± 0.3376 | -1.965 ± 0.3319 |
| Retinal Sensitivity Change at 60 Months Post-Surgery | -2.912 ± 0.3562 | -2.369 ± 0.3347 |
| Retinal Sensitivity Change at 72 Months Post-Surgery | -3.047 ± 0.3674 | -2.909 ± 0.3595 |
Baseline to 108 Months - analyses also presented for additional times: 84, 96 and 108 Months (based on participants' original implant date)
| letters | Cohort 1 - Fellow Eye | Cohort 1 - NT-501 Implant |
|---|---|---|
| Baseline Actual | 80.5 ± 7.34 | 75.0 ± 7.92 |
| 72 Months Post-Surgery Actual | 72.8 ± 11.91 | 71.8 ± 7.76 |
| 72 Months Post-Surgery Change from Baseline | -7.7 ± 7.23 | -3.2 ± 2.48 |
| 84 Months Post-Surgery Actual | 72.7 ± 9.37 | 72.3 ± 6.65 |
| 84 Months Post-Surgery Change from Baseline | -7.8 ± 4.83 | -2.7 ± 2.80 |
| 96 Months Post-Surgery Actual | 72.7 ± 8.82 | 72.3 ± 6.22 |
| 96 Months Post-Surgery Change from Baseline | -7.8 ± 3.43 | -2.7 ± 3.20 |
| 108 Months Post-Surgery Actual | 72.5 ± 8.31 | 68.8 ± 10.30 |
| 108 Months Post-Surgery Change from Baseline | -8.0 ± 3.74 | -6.2 ± 3.37 |
Baseline to 72 Months - analyses also presented for additional times: 36, 48, and 60 Months (based on participants' original implant date during precursor study) . Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up
| letters | Cohort 2 - NT-501 Implant | Cohort 2 - Sham |
|---|---|---|
| Baseline | 77.2 ± 0.97 | 77.0 ± 0.93 |
| Change at 36 Months Post-Surgery | -4.8 ± 0.80 | -3.2 ± 0.77 |
| Change at 48 Months Post-Surgery | -5.7 ± 0.81 | -3.9 ± 0.78 |
| Change at 60 Months Post-Surgery | -8.5 ± 0.82 | -3.9 ± 0.79 |
| Change at 72 Months Post-Surgery | -10.1 ± 0.87 | -6.9 ± 0.83 |
Baseline to 72 Months - analyses also presented for additional times: 36, 48, and 60 Months (based on participants' original implant date during precursor study) . Cohort 2 sham surgery arm includes 16 participants (16 eyes) that received an NT-501 following their Month 36 follow-up. Note: there were
| words per minute | Cohort 2 - NT-501 Implant | Cohort 2 - Sham |
|---|---|---|
| Baseline | 94.740 ± 6.4973 | 107.222 ± 6.2866 |
| Reading Speed Change at 36 Months Post-Surgery | -8.838 ± 5.4428 | -17.798 ± 5.2686 |
| Reading Speed Change at 48 Months Post-Surgery | -18.931 ± 5.5846 | -25.488 ± 5.3072 |
| Reading Speed Change at 60 Months Post-Surgery | -28.627 ± 5.6369 | -18.324 ± 5.4825 |
| Reading Speed Change at 72 Months Post-Surgery | -24.713 ± 5.9294 | -34.478 ± 5.6311 |
Collected over Any serious AE occurring after surgery through study completion, up to 108 months based on participants original implant date. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - Implant Only | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Cohort 2 - Sham Only | 0/19 (0%) | 3/19 (15.8%) | 18/19 (94.7%) |
| Cohort 2 - NT-501 Implant | 1/15 (6.7%) | 4/15 (26.7%) | 14/15 (93.3%) |
| Cohort 2 - Sham + NT-501 Implant | 1/30 (3.3%) | 7/30 (23.3%) | 20/30 (66.7%) |
| Event | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant |
|---|---|---|---|---|
| Duodenal ulcer perforationGastrointestinal disorders | 1/6 | 0/19 | 0/15 | 0/30 |
| Incarcerated herniaGeneral disorders | 1/6 | 0/19 | 0/15 | 0/30 |
| Vascular pseudoaneurysmInjury, poisoning and procedural complications | 1/6 | 0/19 | 0/15 | 0/30 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/19 | 1/15 | 0/30 |
| DiverticulitisInfections and infestations | 0/6 | 0/19 | 1/15 | 0/30 |
| Non-infectious endophthalmitisEye disorders | 0/6 | 0/19 | 1/15 | 0/30 |
| PainGeneral disorders | 0/6 | 0/19 | 1/15 | 0/30 |
| Device expulsionProduct Issues | 0/6 | 0/19 | 1/15 | 0/30 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 1/19 | 0/15 | 0/30 |
| HyponatraemiaMetabolism and nutrition disorders | 0/6 | 1/19 | 0/15 | 0/30 |
| Event | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant |
|---|---|---|---|---|
| CataractEye disorders | 0/6 | 4/19 | 2/15 | 0/30 |
| Vitreous floatersEye disorders | 0/6 | 0/19 | 3/15 | 0/30 |
| Dry eyeEye disorders | 1/6 | 0/19 | 2/15 | 0/30 |
| Eye irritationEye disorders | 1/6 | 1/19 | 1/15 | 0/30 |
| Cataract corticalEye disorders | 1/6 | 0/19 | 0/15 | 0/30 |
| Conjunctivitis allergicEye disorders | 1/6 | 0/19 | 0/15 | 0/30 |
| Dacryostenosis acquiredEye disorders | 1/6 | 0/19 | 0/15 | 0/30 |
| Eye allergyEye disorders | 1/6 | 0/19 | 0/15 | 0/30 |
| Periorbital dermatitisEye disorders | 1/6 | 0/19 | 0/15 | 0/30 |
| InfluenzaInfections and infestations | 1/6 | 1/19 | 1/15 | 1/30 |
| Age, Categorical(Participants) | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 16 | 10 | 16 | 48 |
| >=65 years | 0 | 3 | 5 | 14 | 22 |
| Age, Continuous(years) | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant | Total |
|---|---|---|---|---|---|
| Mean | 53.8 ± 5.12 | 59.4 ± 7.61 | 59.5 ± 10.82 | 63.6 ± 8.59 | 61.4 ± 8.99 |
| Sex: Female, Male(Participants) | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant | Total |
|---|---|---|---|---|---|
| Female | 4 | 11 | 9 | 20 | 44 |
| Male | 2 | 8 | 6 | 10 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 2 |
| Not Hispanic or Latino | 6 | 18 | 14 | 29 | 67 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1 - Implant Only | Cohort 2 - Sham Only | Cohort 2 - NT-501 Implant | Cohort 2 - Sham + NT-501 Implant | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| White | 4 | 16 | 11 | 28 | 59 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 4 | 1 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in May 2021, 47 months.
Results were first posted in May 2025, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciliary Neurotrophic Factor
Neurotech Pharmaceuticals